Home » BAYER AND ONYX BEGIN NEXAVAR STUDY
BAYER AND ONYX BEGIN NEXAVAR STUDY
Bayer Pharmaceuticals and Onyx Pharmaceuticals have announced the initiation of a randomized, double-blind, placebo-controlled Phase III clinical trial studying Nexavar (sorafenib) tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC).
The multicenter study will compare Nexavar when co-administered with two chemotherapeutic agents -- carboplatin and paclitaxel -- versus carboplatin and paclitaxel alone. The study, which is expected to enroll approximately 900 patients, will assess overall survival as the primary endpoint. Secondary endpoints include progression-free survival, tumor response and safety.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May